The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).
 
Nadine M. Tung
Research Funding - AstraZeneca; Myriad Genetics (Inst)
 
Mark E. Robson
Honoraria - AstraZeneca
Consulting or Advisory Role - Change HealthCare
Research Funding - Abbvie (Inst); AstraZeneca (Inst); InVitae (Inst); Medivation (Inst); Myriad Genetics (Inst); Pfizer (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
Other Relationship - Clinical Care Options; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo; Merck; Pfizer
 
Steffen Ventz
No Relationships to Disclose
 
Cesar Augusto Santa-Maria
Consulting or Advisory Role - Athenex; Bristol-Myers Squibb; Genomic Health; Halozyme; Polyphor
Research Funding - Medimmune; Pfizer; Pfizer; Tesaro (Inst)
 
Paul Kelly Marcom
Consulting or Advisory Role - Celltrion; Genentech/Roche; Immunomedics; Merck; Novartis
Speakers' Bureau - Catamount Medical Education; Clinical Care Options
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); Glycomimetics (Inst); Innocrin Pharma (Inst); Novartis (Inst); Verily (Inst)
 
Rita Nanda
Consulting or Advisory Role - Aduro Biotech; Athenex; Daiichi Sankyo; Genentech/Roche; ION Pharma; Macrogenics; Merck; Pfizer; Seagen
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Other Relationship - G1 Therapeutics
 
Payal D Shah
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Johnson & Johnson (I); Merck (I); Novartis (I); Novo Nordisk; Novo Nordisk (I); Pfizer (I)
Consulting or Advisory Role - Tmunity Therapeutics, Inc.
 
Tarah Jean Ballinger
Honoraria - Novartis
Consulting or Advisory Role - Medscape
 
Eddy Shih-Hsin Yang
Consulting or Advisory Role - AstraZeneca; Strata Oncology
Research Funding - Clovis Oncology (Inst); Lilly (Inst); Novartis (Inst)
Other Relationship - Strata Oncology
 
Michelle E. Melisko
Stock and Other Ownership Interests - Merrimack (I)
Honoraria - Agendia; Genentech (I); Pfizer (I)
Speakers' Bureau - Agendia; Genentech (I); Pfizer (I)
Research Funding - Celldex (Inst); Genentech (Inst); Lilly (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to immunoliposomal drugs being studied and potentially brought to market by Merrimack (I)
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Bayer; Bioarray Therapeutics; bioTheranostics; Celgene; Eisai; Genentech/Roche; Genomic Health; Lilly; Merck; Myriad Pharmaceuticals; NanoString Technologies; Novartis; Pfizer; Puma Biotechnology
 
Shaveta Vinayak
Consulting or Advisory Role - Tesaro
Research Funding - OncoSec (Inst)
Travel, Accommodations, Expenses - OncoSec; OncoSec; Oncosec
 
Michelle Demeo
No Relationships to Disclose
 
Colby Jenkins
No Relationships to Disclose
 
Susan M. Domchek
Honoraria - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst)
 
Gerburg M. Wulf
Stock and Other Ownership Interests - Selecta Biosciences (I)
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - Pin1 as a marker for abnormal cell growth Patent number: 8129131
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I)
Leadership - AMAG Pharmaceuticals (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I)
Honoraria - AstraZeneca; Celltrion; Genentech/Roche
Consulting or Advisory Role - Context Therapeutics; Daiichi Sankyo; Genentech/Roche; ION Pharma; Macrogenics; Merck; Novartis; Seagen; Taiho Pharmaceutical
Research Funding - Genentech (Inst); Pfizer (Inst)
 
Antonio C. Wolff
Consulting or Advisory Role - Ionis Pharmaceuticals
Research Funding - Biomarin (Inst); Celldex (Inst)
Patents, Royalties, Other Intellectual Property - Antonio Wolff has been named as inventor on one or more issued patents or pending patent applications relating to methylation in breast cancer, and has assigned his rights to JHU, and participates in a royalty sharing agreement with JHU.
 
Eric P. Winer
Stock and Other Ownership Interests - Verastem
Honoraria - Genentech/Roche; Genomic Health
Consulting or Advisory Role - Carrick Therapeutics; G1 Therapeutics; Genomic Health; GlaxoSmithKline; Jounce Therapeutics; Leap Therapeutics; Lilly; Seagen
Research Funding - Genentech (Inst); Novartis (Inst)
 
Judy Ellen Garber
Consulting or Advisory Role - Aleta BioTherapeutics (I); GTx (I); H3 Biomedicine (I); Helix BioPharma; Konica Minolta; Kronos Bio (I); Novartis (I)
Research Funding - Ambry Genetics; InVitae; Myriad Genetics; Novartis (I)
Other Relationship - AACR; Adrienne Helis Malvin Medical Research Foundation (I); Breast Cancer Research Foundation; Diana Helis Henry Medical Foundation (I); Facing our Risk of Cancer Empowered; James P. Wilmot Foundation (I); Susan G. Komen for the Cure (I)